Latest revenue
$10.1M
as of 2026-03-31
Latest net income
$-3.0M
as of 2026-03-31
Net margin
-29.8%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $40.2M
- Enterprise value
- $40.2M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $3.22
- 52-wk low
- $0.60
- Beta
- —
- Shares out
- 38.6M
5-year trend
What this company does
Item 1. Business Overview We are a wearable medical robotics company that offers functional improvement for those with neuromuscular disorders and upper limb paralysis. We develop and market the MyoPro product line. A MyoPro is a myoelectric-controlled upper limb brace, or orthosis. The orthosis is a rigid brace used for the purpose of supporting a patient’s weak or paralyzed arm to enable and help improve functional activities of daily living, or ADLs, in the home and community. It is custom-fabricated by trained professionals during a custom fabrication process for each individual user to meet their specific needs. Our products are designed to help improve function in adults and…
AI summary unavailable — showing raw filing excerpt
Generated from MYO's filing dated 2026-03-09
Key risks
Item 1A. Risk Factors The following important factors, among others, could cause our actual operating results to differ materially from those indicated or suggested by forward-looking statements made in this Annual Report on Form 10-K or presented elsewhere by management from time to time. Investors should carefully consider the risks described below before making an investment decision. The risks described below are not the only ones we face. Additional risks not presently known to us or that we currently believe are not material may also significantly impair our business operations. Our business could be harmed by any of these risks. The trading price of our common stock could decline due…
AI summary unavailable — showing raw filing excerpt
Generated from MYO's filing dated 2026-03-09
Profitability
Gross margin
65.7%
7.8%Operating margin
-35.2%
84.5%Net margin
-38.1%
100.3%Return on equity
-63.0%
151.9%Return on assets
-40.3%
175.4%Leverage
Debt / equity
0.56×
20.6%Long-term debt / equity
0.45×
Debt / assets
36.0%
13.2%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $10.1M | +2.9% | $-3.0M | +13.2% | -29.8% |
Q4 2025 2025-12-31 | $11.4M | -5.9% | $-3.8M | -1366.4% | -33.6% |
Q3 2025 2025-09-30 | $10.1M | +9.6% | $-3.7M | -279.0% | -36.3% |
Q2 2025 2025-06-30 | $9.7M | +28.3% | $-4.6M | -313.0% | -48.0% |
Q1 2025 2025-03-31 | $9.8M | +161.9% | $-3.5M | +9.7% | -35.2% |
Q4 2024 2024-12-31 | $12.1M | — | $-260.1K | — | -2.2% |
Q3 2024 2024-09-30 | $9.2M | +81.3% | $-966.4K | +52.4% | -10.5% |
Q2 2024 2024-06-30 | $7.5M | +26.2% | $-1.1M | -10.6% | -14.9% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Orthopedic, Prosthetic & Surgical Appliances & Supplies · SIC 3842
Your notes
Keep private notes on MYO — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$526.6K
Insider selling
$0
Net activity
+$526.6K
Distinct insiders
5
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns MYO
Institutional value
$4.2M
Total shares held
6.5M
Distinct holders
47
-28 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 1.7M | $1.1M | -24.4K (-1.4%) | Trimmed |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 1.1M | $773.6K | — | New |
| 3 | Jefferies Financial Group Inc. | 704.3K | $475.8K | +0 (+0.0%) | No change |
| 4 | Clearstead Advisors, LLC | 425.6K | $287.5K | -4 (-0.0%) | Trimmed |
| 5 | Nuveen, LLC | 370.3K | $250.2K | +0 (+0.0%) | No change |
| 6 | UBS Group AG | 311.7K | $210.7K | -247.7K (-44.3%) | Trimmed |
| 7 | LPL Financial LLC | 306.0K | $206.7K | +129.0K (+72.9%) | Added |
| 8 | VANGUARD FIDUCIARY TRUST CO | 237.3K | $160.4K | — | New |
| 9 | VANGUARD PORTFOLIO MANAGEMENT LLC | 205.6K | $139.0K | — | New |
| 10 | SEI INVESTMENTS CO | 147.8K | $99.8K | +0 (+0.0%) | No change |
| 11 | PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. | 140.3K | $94.8K | -45.2K (-24.4%) | Trimmed |
| 12 | DEUTSCHE BANK AG\ | 135.7K | $92.2K | +0 (+0.0%) | No change |
| 13 | Bank of New York Mellon Corp | 70.5K | $47.7K | -118 (-0.2%) | Trimmed |
| 14 | Stratos Wealth Partners, LTD. | 60.0K | $40.5K | +0 (+0.0%) | No change |
| 15 | NEW YORK STATE COMMON RETIREMENT FUND | 45.1K | $30.5K | +0 (+0.0%) | No change |
| 16 | Accel Wealth Management | 34.2K | $23.1K | -5.9K (-14.7%) | Trimmed |
| 17 | Summit Financial Strategies, Inc. | 25.0K | $16.9K | +0 (+0.0%) | No change |
| 18 | IMC-Chicago, LLC | 22.3K | $15.1K | — | New |
| 19 | Accurate Wealth Management, LLC | 21.1K | $14.6K | +0 (+0.0%) | No change |
| 20 | RHUMBLINE ADVISERS | 18.4K | $12.5K | +419 (+2.3%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once MYO's latest filing finishes processing.